NASDAQ NMS - GLOBAL MARKET · ACRS
+1.13% · +$0.0713 · Vol 2.2M
Market closed · last close 4:00 PM ET · price as of 16:37:11 ET
Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

Pharmaceuticals
$6.40
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
ACRS
Aclaris Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ACRS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ACRS catalysts
About Aclaris Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
73
Country
US

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.36
Day high
$6.50
Day low
$6.29
Previous close
$6.33
52W high
$6.50
-1.52% from high
52W low
$1.80
98% of range
Market cap
$943.5M
EPS
$-0.5500
Beta
1.55
Shares out
147.2M
Volume
2.2M
1.16× rel vol
Avg volume
1.9M
VWAP
$6.42
Price history computed in-house
1W
+8.13%
1M
+22.40%
3M
+41.94%
1Y
+255.63%
YTD
+112.67%
SMA 50 $5.44 · above
SMA 200 $4.02 · above
52W position 98%

ACRS overview

Veridion Score
59
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ACRS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ACRS Form 4 filings
Public disclosures

Congress activity in ACRS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ACRS in the cached public ledger.

Federal contracts

ACRS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ACRS in this window.
Lobbying spend

ACRS lobbying filings, year to date.

Registered lobbying filings matched to Aclaris Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ACRS in this window.
Loading news for ACRS
Analyst ratings
Sovereign unlock shows live analyst consensus for ACRS.
Options
Sovereign unlock shows live options positioning for ACRS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.